Dedicated to empowering female researchers and increasing the visibility of their scientific work, the “For Women in Science” Program marks its 24th year in Turkey by backing innovative projects. Among this year’s fellows, Assoc. Prof. Dr. Belgin Sever focuses on discovering novel therapeutic options for Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.
Computer-Designed Molecules to Be Synthesized and Tested in the Laboratory
In certain forms of ALS—a condition causing the progressive degeneration of motor neurons responsible for muscle control—the intracellular accumulation of mutant SOD1 protein triggers cellular damage. Addressing the limited treatment options currently available, Dr. Sever’s project follows a two-stage methodology:
Computer-Aided Molecular Design: Drawing on the chemical structures of existing therapeutic compounds, numerous novel molecules with the potential to target the mutant SOD1 protein will be designed in silico and evaluated for therapeutic suitability.
Laboratory Synthesis and Cell Model Testing: Promising candidate molecules identified through computational screening will be synthesized in the laboratory and subsequently tested on ALS cell models to examine their biological efficacy.
The study aims to expand scientific understanding of targeting mutant SOD1-driven neurotoxicity and contribute to the development of future therapeutic strategies for ALS.